Ensoma: Valuation, Funding & Investors
Ensoma is a biotechnology company focused on developing potentially curative medicines for genetic diseases, immune disorders, and cancer through in vivo hematopoietic stem cell (HSC) engineering. Utilizing proprietary base editing and high-efficiency gene integration systems, Ensoma's platform employs high-capacity virus-like particles (VLPs) to deliver genetic payloads directly to HSCs, enabling one-time administration of durable genetic therapies. The company is advancing its clinical-stage pipeline, including a Phase 1/2 trial for EN-374 targeting X-linked chronic granulomatous disease, and aims to make a global impact in the field of genetic medicines.
Leadership & Board
Latest Estimated Valuation
- Total Amount Raised
- $53M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $53M
- Latest Funding Round
- Investment
Main Enterprise Clients
A snapshot of major enterprise customers that use this private company’s products or services, highlighting its commercial reach and market adoption.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 22, 2025 | Investment | $53.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Cormorant Asset Management | Investment |
| Viking Global Investors | Investment |
| Catalio Capital Management | Investment |
| Delos Capital | Investment |
| Symbiosis | Investment |
| F-Prime | Investment |
| Qatar Investment Authority | Investment |
| 5AM Ventures | Investment |
Similar Companies
A snapshot of private companies similar to Ensoma, helping you discover and navigate related company profiles.
